MBIO Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Mustang Bio has a consensus price target of $17.50, signalling upside risk potential of 1096.89%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 243.12%. Given that Mustang Bio has higher upside potential than Armata Pharmaceuticals, analysts believe Mustang Bio is more attractive than Armata Pharmaceuticals.

Mustang Bio has a beta of 1.806, which suggesting that the stock is 80.562% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.301%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Mustang Bio's net income of -$1.4M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 739.11x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Mustang Bio has a consensus price target of $17.50, signalling upside risk potential of 1096.89%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Mustang Bio has higher upside potential than Perspective Therapeutics, analysts believe Mustang Bio is more attractive than Perspective Therapeutics.

Mustang Bio has a beta of 1.806, which suggesting that the stock is 80.562% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Mustang Bio's net income of -$1.4M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Mustang Bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -- compared to Mustang Bio's net margin of -87.96%. Mustang Bio's return on equity of -- beat Fortress Biotech's return on equity of --.

Mustang Bio has a consensus price target of $17.50, signalling upside risk potential of 1096.89%. On the other hand Fortress Biotech has an analysts' consensus of -- which suggests that it could grow by 691.9%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Mustang Bio has a beta of 1.806, which suggesting that the stock is 80.562% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.703, suggesting its more volatile than the S&P 500 by 70.299%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Mustang Bio's net income of -$1.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.35x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of 18.02%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Mustang Bio has a consensus price target of $17.50, signalling upside risk potential of 1096.89%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 686.52%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 1.806, which suggesting that the stock is 80.562% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Mustang Bio's net income of -$1.4M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 3.06x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.